Skip to main content

Table 1 Baseline characteristics of subjects at the inclusion in the three treatment groups

From: Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance

Parameters

DHAPQ (N = 176)

AL (N = 178)

ASAQ (N = 180)

Age (median ± SD, years)

14 ± 10

13 ± 12

14 ± 12

Sex ratio (F/M)

1.41

1.17

1.85

Weight (mean ± SD, Kg)

42.4 ± 19

37.5 ± 20

38.9 ± 18

Temperature (mean ± SD)

38.1 ± 1.1

38 ± 1.08

38 ± 2

Patients with fever

76.14%

75.8%

75%

Parasitemia (median ± trophozoites/μL)

21347.5

26192.5

13132.5

Hb mean (g/dl)

11.88

11.89

11.48

Anemia (Hb < 11 g/dl) (%)

24.43

22.47

29.44

ALAT (UI/L, mean ± SD)

19

21

20.76

ASAT (UI/L, mean ± SD)

34.37

33.52

32.17

Patients with ALAT < 40 UI/L (%)

89.77

88.20

84.44

Patients with ASAT < 40 UI/L (%)

80.68

83.15

88.20

Mean bilirubin

1.3

1.5

0.81

Patients with normal level of bilirubin (0.23 – 1 mg/dl)

77.27

79.78

79.44

Mean creatinine (mg/l)

8.15

8.75

7.9

Patients with normal level of creatinine (6 – 14 mg/l) (%)

77.27

80.34

93.33